Research ArticleOriginal Article

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study

Wei Zhang, Liping Su, Lihong Liu, Yuhuan Gao, Quanshun Wang, Hang Su, Yuhuan Song, Huilai Zhang, Jing Shen, Hongmei Jing, Shuye Wang, Xinan Cen, Hui Liu, Aichun Liu, Zengjun Li, Jianmin Luo, Jianxia He, Jingwen Wang, O. A. O’Connor and Daobin Zhou
Cancer Biology & Medicine August 2021, 18 (3) 841-848; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0413

References

  1. 1.↵
    2. Anderson JR,
    3. Armitage JO,
    4. Weisenburger DD.
    Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998; 9: 717–20.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Sun J,
    3. Yang Q,
    4. Lu Z,
    5. He M,
    6. Gao L,
    7. Zhu M, et al.
    Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012; 138: 429–34.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Vose J,
    3. Armitage J,
    4. Weisenburger D, International TCLP.
    International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124–30.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    2. d’Amore F,
    3. Relander T,
    4. Lauritzsen GF,
    5. Jantunen E,
    6. Hagberg H,
    7. Anderson H, et al.
    Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30: 3093–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Ma H,
    3. O’Connor OA,
    4. Marchi E.
    New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Rev Hematol. 2019; 12: 137–46.
    OpenUrl
  6. 6.↵
    2. O’Connor OA,
    3. Horwitz S,
    4. Masszi T,
    5. Van Hoof A,
    6. Brown P,
    7. Doorduijn J, et al.
    Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015; 33: 2492–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Coiffier B,
    3. Pro B,
    4. Prince HM,
    5. Foss F,
    6. Sokol L,
    7. Greenwood M, et al.
    Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30: 631–6.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    2. Shi Y,
    3. Dong M,
    4. Hong X,
    5. Zhang W,
    6. Feng J,
    7. Zhu J, et al.
    Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015; 26: 1766–71.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Gao S,
    3. Li X,
    4. Zang J,
    5. Xu W,
    6. Zhang Y.
    Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Med Chem. 2017; 17: 802–12.
    OpenUrl
  10. 10.↵
    2. Swerdlow SH,
    3. Campo E,
    4. Pileri SA,
    5. Harris NL,
    6. Stein H,
    7. Siebert R, et al.
    The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375–90.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Schmitz N,
    3. Trumper L,
    4. Ziepert M,
    5. Nickelsen M,
    6. Ho AD,
    7. Metzner B, et al.
    Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116: 3418–25.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Liu X,
    3. Yang M,
    4. Wu M,
    5. Zheng W,
    6. Xie Y,
    7. Zhu J, et al.
    A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. Cancer Chemother Pharmacol. 2019; 83: 443–9.
    OpenUrl
  13. 13.↵
    2. Dupuis J,
    3. Morschhauser F,
    4. Ghesquieres H,
    5. Tilly H,
    6. Casasnovas O,
    7. Thieblemont C, et al.
    Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol. 2015; 2: e160–5.
    OpenUrl
  14. 14.↵
    2. Bromberg JEC,
    3. Issa S,
    4. Bakunina K,
    5. Minnema MC,
    6. Seute T,
    7. Durian M, et al.
    Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019; 20: 216–28.
    OpenUrl
  15. 15.↵
    2. Budden KF,
    3. Shukla SD,
    4. Rehman SF,
    5. Bowerman KL,
    6. Keely S,
    7. Hugenholtz P, et al.
    Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med. 2019; 7: 907–20.
    OpenUrl
  16. 16.↵
    2. Amengual JE,
    3. Lichtenstein R,
    4. Lue J,
    5. Sawas A,
    6. Deng C,
    7. Lichtenstein E, et al.
    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018; 131: 397–407.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Horwitz S,
    3. O’Connor OA,
    4. Pro B,
    5. Illidge T,
    6. Fanale M,
    7. Advani R, et al.
    Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393: 229–40.
    OpenUrlCrossRef
  18. 18.↵
    2. Kim SJ,
    3. Kim JH,
    4. Ki CS,
    5. Ko YH,
    6. Kim JS,
    7. Kim WS.
    Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol. 2016; 27: 508–13.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords